Q3 EPS Forecast for Mirum Pharmaceuticals Reduced by Analyst

Key Points

• Analyst HC Wainwright cut its Q3 2026 EPS forecast for Mirum to ($0.25) from ($0.18) but kept a "Buy" rating and a $175 price target.
• Mirum's most recent quarter missed on EPS (($0.11), versus a $0.02 consensus) while revenue came in at $148.93 million, up 49.8% year‑over‑year and above expectations.
• Company insiders sold 76,806 shares worth about $7.06 million in the last quarter (including two 7,287‑share sales), leaving insiders with 22.87% ownership.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at HC Wainwright dropped their Q3 2026 EPS estimates for Mirum Pharmaceuticals in a report released on Monday, May 4th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.25) per share for the quarter, down from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $175.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals' Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.80) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million for the quarter, compared to analysts' expectations of $141.78 million. During the same quarter last year, the firm posted $1.00 earnings per share. The firm's revenue for the quarter was up 49.8% compared to the same quarter last year.

Several other analysts have also commented on the stock. Citizens Jmp reaffirmed a "market outperform" rating and issued a $132.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, February 28th. Royal Bank Of Canada lowered their price objective on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an "outperform" rating on the stock in a research report on Thursday, February 26th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $95.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 28th. Finally, TD Cowen lifted their price objective on shares of Mirum Pharmaceuticals from $117.00 to $125.00 and gave the stock a "buy" rating in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $125.25.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $105.81 on Wednesday. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of -220.43 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. Mirum Pharmaceuticals has a 52 week low of $40.00 and a 52 week high of $110.49. The firm's 50-day simple moving average is $93.79 and its two-hundred day simple moving average is $85.61.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $30,000. MCF Advisors LLC grew its position in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company's stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $33,000.

Insider Activity at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 7,287 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the sale, the chief financial officer directly owned 49,788 shares of the company's stock, valued at $4,579,500.24. This trade represents a 12.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Joanne Quan sold 7,287 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $670,258.26. Following the completion of the sale, the insider directly owned 18,864 shares in the company, valued at $1,735,110.72. This represents a 27.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 76,806 shares of company stock valued at $7,064,616 in the last quarter. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.